Jaiprakash Patel, MD
Internal Medicine · West Columbia, SCNPI 1245290402
Payments from drug & device makers
Across 148 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$378
- Boehringer Ingelheim$308
- Novo Nordisk$263
- Amarin Pharma, Inc.$233
- Johnson & Johnson$184
- Amgen$167
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,63097%
- Education$943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $378 |
| Boehringer Ingelheim | 12 | $308 |
| Novo Nordisk | 15 | $263 |
| Amarin Pharma, Inc. | 13 | $233 |
| Johnson & Johnson | 11 | $184 |
| Amgen | 10 | $167 |
| Lilly USA, LLC | 9 | $154 |
| Esperion Therapeutics, Inc. | 6 | $152 |
| Pfizer | 10 | $139 |
| Eisai Inc. | 7 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $94 |
| Abbott | 4 | $78 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Merck | 4 | $59 |
| AbbVie | 2 | $47 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Aytu Biopharma, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Qiagen, LLC | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$121
How this compares
$2,724 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 79 | $106,416 |
| OzempicSemaglutide | 109 | $106,131 |
| JanuviaSitagliptin Phosphate | 29 | $42,737 |
| FarxigaDapagliflozin Propanediol | 30 | $34,670 |
| TrulicityDulaglutide | 11 | $16,972 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $16,430 |
| EliquisApixaban | 11 | $15,103 |
| XareltoRivaroxaban | 13 | $12,358 |
| MounjaroTirzepatide | 12 | $12,311 |
| Rosuvastatin Calcium | 409 | $9,216 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $7,605 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $7,347 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $5,790 |
| Ezetimibe | 138 | $5,611 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $5,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $308 | $106,41679 claims |
| Novo NordiskOzempic | $263 | $106,131109 claims |
| MerckJanuvia, Janumet | $59 | $59,16742 claims |
| AstraZenecaFarxiga | $378 | $34,67030 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $154 | $29,28323 claims |
| PfizerEliquis | $139 | $15,10311 claims |
| Johnson & JohnsonXarelto | $184 | $12,35813 claims |
| AbbVieSynthroid | $47 | $2,74349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in West Columbia
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.